

Special Issue

Novel Targets in Triple-Negative Breast Cancer

Message from the Guest Editors

Although there have been several advances in the treatment of breast cancer, for the triple-negative subtype very limited therapeutic options exist. In this breast cancer group checkpoint and PARP inhibitors have been recently incorporated into our clinical armamentarium, but there are still several challenges, such as the stratification of patients based on the right biomarkers. This Special Issue will collect a series of articles that provide new information about the current stage of novel therapeutic efforts in this indication. We will combine “up-to-date” reviews with original articles that report novel findings. We kindly encourage researchers and physician-scientists to submit their work to this Special Issue.

Guest Editors

Prof. Alberto Ocaña

Centro Regional de Investigaciones Biomédicas (CRIB), Castilla La Mancha University, Albacete, Spain

Dr. Atanasio Pandiella

Centro de Investigación del Cáncer (Universidad de Salamanca-CSIC), Campus Universitario Miguel de Unamuno s/n, 37007 Salamanca, Spain

Deadline for manuscript submissions

closed (31 August 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/48747

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)